Nelson and Liu share the senior authorship.
CC genotype donors for the interleukin-28B single nucleotide polymorphism are associated with better outcomes in hepatitis C after liver transplant
Article first published online: 29 OCT 2012
© 2012 John Wiley & Sons A/S
Volume 33, Issue 1, pages 72–78, January 2013
How to Cite
Firpi, R. J., Dong, H., Clark, V. C., Soldevila-Pico, C., Morelli, G., Cabrera, R., Norkina, O., Shuster, J. J., Nelson, D. R. and Liu, C. (2013), CC genotype donors for the interleukin-28B single nucleotide polymorphism are associated with better outcomes in hepatitis C after liver transplant. Liver International, 33: 72–78. doi: 10.1111/liv.12013
- Issue published online: 10 DEC 2012
- Article first published online: 29 OCT 2012
- Accepted manuscript online: 5 OCT 2012 08:24AM EST
- Manuscript Accepted: 5 SEP 2012
- Manuscript Received: 12 APR 2012
- National Institute of Research Resources
- National Institutes of Health. Grant Number: R01 AI061158
- sustained viral response
Interleukin-28B (IL-28B) polymorphism is the strongest pretreatment predictor of viral clearance in the hepatitis C (HCV) population. Donor and recipient IL-28B genomic background may play an important role in post-transplant HCV recurrence. We sought to examine the role of IL-28B polymorphisms of donor and recipients in liver transplant patients with recurrent HCV and its impact on the response to interferon-based therapy.
The cohort study consisted of 135 adult liver transplant patients who received interferon-based therapy for recurrent HCV between 1996 and 2005 at the University of Florida. IL-28B single nucleotide polymorphism (rs. 12979860) was characterized using liver tissue from all donors and recipients.
The CC genotype was observed in approximately 30% of donors and recipients. Sustained viral response (SVR) to HCV therapy was 100% if both recipient and donor were CC genotype, while the SVR was only 25% if neither donor nor recipient had a CC genotype. (Recipient, P = 0.025, Donor, P < 0.001). Recipients and donors with CC genotype had less fibrosis than recipients with genotypes CT and TT, but the difference was not statistically significant. IL-28B genotype did not seem to play a role in the overall survival in these patients.
In conclusion, recipient and donor CC genotype is associated with a better treatment response to interferon-based therapy after liver transplant. Our study suggests that using CC genotype donor livers for HCV patients may improve the overall clinical outcome after liver transplantation.